A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy.

Douguet, Laetitia; Janho Dit Hreich, Serena; Benzaquen, Jonathan; Seguin, Laetitia; Juhel, Thierry; Dezitter, Xavier; Duranton, Christophe; Ryffel, Bernhard; Kanellopoulos, Jean; Delarasse, Cecile; Renault, Nicolas; Furman, Christophe; Homerin, Germain; Féral, Chloé; Cherfils-Vicini, Julien; Millet, Régis; Adriouch, Sahil; Ghinet, Alina; Hofman, Paul; Vouret-Craviari, Valérie

doi:10.1038/s41467-021-20912-2

Public

A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy.

Shared by NobleBlocks on Jan 28, 2021 • 12:00 AM UTC

Authors:

Laetitia Douguet

Serena Janho Dit Hreich

Jonathan Benzaquen

Abstract

Only a subpopulation of non-small cell lung cancer (NSCLC) patients responds to immunotherapies, highlighting the urgent need to develop therapeutic strategies to improve patient outcome. We develop a chemical positive modulator (HEI3090) of the purinergic P2RX7 receptor that potentiates αPD-1 treat...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!